Who was the chief executive officer of Ipsen from 2010 to 2016?
Ipsen Ipsen is a French pharmaceutical company headquartered in Paris , France . It develops and markets medications used in oncology , neuroscience and rare diseases along with consumer healthcare products . It is publicly traded on the Euronext Paris as part of the SBF 120 index . Ipsen , founded by Henri Beaufour in 1929 , has more than 5,700 employees worldwide , marketing over 20 drugs in 115 countries . Overview . Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €2.56 billion in 2019 . The Beaufour family , which ranks as the 42nd richest family in France , still owns 57% of its shares and 73% of its voting rights , and two of its members , Anne Beaufour and Henri Beaufour , sit on its board of directors . In 2019 , Ipsen spent close to €388.8 million—15.1% of consolidated sales—on research and development . In February 2015 , the company announced it would Canbex Therapeutics $6.8 million upfront upon completion of a Phase IIA study of Canbexs lead multiple sclerosis compound , VSN16R . in October 2016 , European Commission approves Ipsens Cabometyx ( Cabozantinib ) Tablets for the treatment of advanced renal cell carcinoma ( RCC ) in adults following prior vascular endothelial growth factor ( VEGF ) -targeted therapy . The CABOSUN study , presented at the European Society for Medical Oncology ( ESMO ) 2016 congress , showed Cabometyx ( Cabozantinib ) can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma ( RCC ) . In November 2018 , the European Commission ( EC ) approved Cabometyx ( cabozantinib ) 20 , 40 , 60 mg as a monotherapy for hepatocellular carcinoma ( HCC ) in adults who have previously been treated with sorafenib . This approval allows for the marketing of Cabometyx ( cabozantinib ) in this indication in all 28 member states of the European Union , Norway and Iceland . In February 2019 , Ipsen announced it would acquire Clementia Pharmaceuticals , a biopharmaceutical company specialized in rare bone diseases , for $1.3 billion . This acquisition is the largest in the history of Ipsen . In April 2019 , Ipsen announced the deal was finalized . Research and development . In 2019 , Ipsens R&D expenditure totaled close to €388.8 million , representing more than 15.1% of group sales . Ipsens main research and development centers are located in Cambridge ( Massachusetts , United States ) , Milton Park / Oxford ( United Kingdom ) and Les Ulis Courtaboeuf ( France ) . Governance . Board of directors . The board of directors sets the strategic guidelines for Ipsens activities and oversees implementation . - Marc de Garidel , chairman of the board of directors - Anne Beaufour - Henri Beaufour - Philippe Bonhomme - Antoine Flochel ( vice-chairman ) . - Margaret A . Liu - Michèle OLLIER - Paul Sekhri - Carol Stuckley - Piet Wigerinck - Carol Xueref Management team . Corporate executives are responsible for managing the groups operations and coordinating the groups various scientific , legal , financial , commercial and strategic actions . - David Loew , CEO - Aymeric Le Chatelier , CFO - Bartek Bednarz , executive vice president , head of global product and portfolio strategy - Dominique Bery , executive vice president , strategy & transformation - François Garnier , executive vice president , general counsel - Benoît Hennion , executive vice president , consumer healthcare - Steven Hildemann , MD , executive vice president , chief medical officer , head of - Dominique Laymand , executive vice president , ethics and social responsibility officer - Philippe Lopes-Fernandes , executive vice president , chief business officer - Howard Mayer , MD , executive vice president , head of research and development global medical affairs and pharmacovigilance - Régis Mulot , executive vice president , chief human resources officer - Aidan Murphy , executive vice president , technical operations - Richard Paulson , executive vice president , chief executive officer of Ipsen North America - Gwenan White , executive vice president , communications and public affairs - Patrice Zagame , executive vice president , specialty care international Ipsen Foundation . In 1983 , Ipsen founded the Ipsen Foundation ( Fondation Ipsen ) with the help of the Fondation de France to track progress in biomedical research . It is headquartered in Boulogne-Billancourt . It has organised 64 colloquia , and it has partnered with the World Health Organization , the Fondation Nationale de Gérontologie , Harvard University , the Salk Institute for Biological Studies , the Massachusetts General Hospital , and the academic journals Nature and Cell .